Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.06 CHF | +3.06% | +21.20% | +73.64% |
Mar. 13 | Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up | MT |
Mar. 12 | Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 17.99M 19.93M | Sales 2023 | 33.56M 37.2M | Capitalization | 128M 142M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.52M | Net income 2023 | -13M -14.41M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.48M | Net cash position 2023 | 12M 13.3M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.69% |
1 day | +3.06% | ||
1 week | +21.20% | ||
Current month | +14.34% | ||
1 month | +16.54% | ||
3 months | +74.14% | ||
6 months | +200.00% | ||
Current year | +73.64% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 6.06 | +3.06% | 287,893 |
24-03-27 | 5.88 | -0.68% | 314,624 |
24-03-26 | 5.92 | +5.71% | 303,919 |
24-03-25 | 5.6 | +8.95% | 304,235 |
24-03-22 | 5.14 | +2.80% | 120,245 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+73.64% | 248M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |